Pfizer's Combo Covid and Flu Vaccine Advances to Final Stage Trial with Positive Results

Pfizer and its partner BioNTech announced that their combination vaccine candidates targeting Covid-19 and the flu have shown positive initial results in an early to mid-stage study. The promising data has prompted the pharmaceutical giant to move forward with a final-stage trial in the coming months. Pfizer aims to simplify immunization practices by offering a single injection that can protect against both respiratory viruses. The trial demonstrated robust immune responses to influenza A, influenza B, and Covid strains, and the safety profiles of the combination vaccine candidates were consistent with Pfizer's Covid vaccine. Other vaccine makers, including Moderna and Novavax, are also developing their own combination shots.